文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

神经调节辅助通气用于急性呼吸衰竭:一项随机对照试验

Neurally adjusted ventilatory assist in acute respiratory failure: a randomized controlled trial.
PubMed 文献 · Intensive Care Med · 2020-09-06
一句话结论在急性呼吸衰竭机械通气患者中,与常规肺保护性通气相比,NAVA增加28天无呼吸机天数(22 vs 18天),但未改善住院生存。

该多中心随机对照试验纳入306例急性呼吸衰竭且插管≤5天、预计需机械通气≥72小时、能自主呼吸的患者,随机分为肺保护性机械通气联合NAVA组(153例)与单纯肺保护性机械通气对照组(153例)。主要终点28天无呼吸机天数在NAVA组更高(中位数22 vs 18天,组间差4天,95%CI 0至8天,p=0.016)。住院死亡率NAVA组39例(25.5%) vs 对照组47例(30.7%),组间差-5.2%(95%CI -15.2至4.8,p=0.31),无统计学显著差异。其他临床、生理或安全性结局两组无显著差异。结论认为NAVA缩短机械通气时间但不改善生存。

要点

  • 急性呼吸衰竭插管≤5天、预计需机械通气≥72小时且能自主呼吸者,NAVA组28天无呼吸机天数中位数22天 vs 对照组18天(差4天,95%CI 0至8天,p=0.016)。
  • NAVA组住院死亡率25.5%(39/153) vs 对照组30.7%(47/153),组间差-5.2%(95%CI -15.2至4.8,p=0.31),无统计学显著差异。
  • 其他临床、生理或安全性结局两组无显著差异。
  • 该试验为多中心随机对照试验,共纳入306例急性呼吸衰竭患者,NAVA组与对照组各153例。

适用人群与场景

  • 急性呼吸衰竭(多种病因)的插管患者,已机械通气≤5天、预计仍需机械通气≥72小时且能自主呼吸者纳入。

处置流程与药物剂量

  • 对照组采用肺保护性机械通气;NAVA组采用肺保护性机械通气联合神经调节辅助通气(NAVA)。

研究设计与关键结果

  • 多中心随机对照试验,2014年3月至2019年10月纳入306例急性呼吸衰竭患者,随机分为NAVA组153例和对照组153例,按意向性治疗原则分析。
  • 主要终点28天无呼吸机天数中位数NAVA组22天 vs 对照组18天,组间差4天(95%CI 0至8天,p=0.016)。
  • 次要终点住院死亡率NAVA组39例(25.5%) vs 对照组47例(30.7%),组间差-5.2%(95%CI -15.2至4.8,p=0.31),无统计学显著差异。
  • 其他临床、生理或安全性结局两组无显著差异。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急性呼吸衰竭插管≤5天、预计需机械通气≥72小时且能自主呼吸的患者,使用NAVA可缩短机械通气时间(28天无呼吸机天数中位数22 vs 18天),但未改善住院生存(死亡率25.5% vs 30.7%,无统计学显著差异)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: We hypothesized that neurally adjusted ventilatory assist (NAVA) compared to conventional lung-protective mechanical ventilation (MV) decreases duration of MV and mortality in patients with acute respiratory failure (ARF).

METHODS: We carried out a multicenter, randomized, controlled trial in patients with ARF from several etiologies. Intubated patients ventilated for ≤ 5 days expected to require MV for ≥ 72 h and able to breathe spontaneously were eligible for enrollment. Eligible patients were randomly assigned based on balanced treatment assignments with a computerized randomization allocation sequence to two ventilatory strategies: (1) lung-protective MV (control group), and (2) lung-protective MV with NAVA (NAVA group). Allocation concealment was maintained at all sites during the trial. Primary outcome was the number of ventilator-free days (VFDs) at 28 days. Secondary outcome was all-cause hospital mortality. All analyses were done according to the intention-to-treat principle.

RESULTS: Between March 2014 and October 2019, we enrolled 306 patients and randomly assigned 153 patients to the NAVA group and 153 to the control group. Median VFDs were higher in the NAVA than in the control group (22 vs. 18 days; between-group difference 4 days; 95% confidence interval [CI] 0 to 8 days; p = 0.016). At hospital discharge, 39 (25.5%) patients in the NAVA group and 47 (30.7%) patients in the control group had died (between-group difference - 5.2%, 95% CI - 15.2 to 4.8, p = 0.31). Other clinical, physiological or safety outcomes did not differ significantly between the trial groups.

CONCLUSION: NAVA decreased duration of MV although it did not improve survival in ventilated patients with ARF.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kacmarek RM, Villar J, Parrilla D, et al. Neurally adjusted ventilatory assist in acute respiratory failure: a randomized controlled trial. Intensive Care Med. 2020. PMID: 32893313. doi:10.1007/s00134-020-06181-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。